Activation of immune cells
Bone marrow containers are described herein. Separation systems for separating activated immune cells from other components are described herein. Methods of activating an immune cell are described herein.
1. A bone marrow container comprising: a composition comprising:
a non-ionic hydrophilic branched polysaccharide at a concentration, wherein, if the composition is contacted with whole blood and centrifuged, said concentration is sufficient to permit fluid movement of whole blood through the non-ionic hydrophilic branched polysaccharide without separation of erythrocytes, wherein the non-ionic hydrophilic branched polysaccharide comprises poly(sucrose-co-epichlorhydrin),
the non-ionic hydrophilic branched polysaccharide having a molecular weight greater than 20 kDa; and
a TLR2 ligand, wherein the composition is contained within the container, and wherein the container is sterile.
2. The bone marrow container of claim 1 , wherein the non-ionic hydrophilic branched polysaccharide has a molecular weight of at least 70 kDa.
3. The bone marrow container of any one of claim 1 , wherein the non-ionic hydrophilic branched polysaccharide has a density less than 1 gram per liter.
4. The bone marrow container of claim 1 , wherein the TLR2 ligand is selected from the group consisting of hyaluronon, hyaluronic acid, monosodium urate crystals, biglycan, endoplasmin, HMGB1, HSP60, HSP70, human cardiac myosin, zymosan, lipoteichoic acids, peptidoglycans, and Pam2CSK4, and Pam3CSK4.
5. The bone marrow container of claim 1 , wherein the non-ionic hydrophilic branched polysaccharide comprises poly(sucrose-co-epichlorhydrin) at a concentration of less than 1 gram per liter, and wherein the TLR2 ligand comprises hyaluronic acid.
6. The bone marrow container of claim 1 , further comprising an integral delivery device.
7. The bone marrow container of claim 1 , further comprising dextran.
8. A kit comprising the bone marrow container of claim 1 , and a bone marrow aspiration needle.
9. The bone marrow container of claim 3 , wherein the concentration of the non-ionic hydrophilic branched polysaccharide is less than 0.99 g/l, 0.9 g/l, 0.8 g/l, 0.7 g/l, 0.6 g/7, 0.5 g/l, 0.4 g/l, 0.3 g/l, 0.2 g/l, 0.1 g/l, 0.05 g/l, 10 −2 g/l, 2×10 −3 g/l, 10 −3 g/l, 10 −5 g/l, 2×10 −6 g/l, 10 −6 g/l, 10 −7 g/l, 10 −8 g/l, 2×10 −9 g/l, or 10 −9 g/l.
10. The bone marrow container of claim 3 , wherein the concentration of the non-ionic hydrophilic branched polysaccharide is 10 −9 to 10 −6 g/L, 10 −9 to 10 −3 g/L, 10 −9 to 10 −2 g/L, 10 −9 to 0.1 g/L, 10 −9 to 0.5 g/L, 10 −9 to 0.9 g/L, 10 −9 to 0.09 g/L, 10 −6 to 10 −3 g/L, 10 −6 to 10 −2 g/L, 10 −6 to 0.1 g/L, 10 −6 to 0.5 g/L, 10 −6 to 0.9 g/L, 10 −6 to 0.09 g/L, 2×10 −6 to 10 −3 g/L, 2×10 −6 to 10 −2 g/L, 2×10 −6 to 0.1 g/L, 2×10 −6 to 0.5 g/L, 2×10 −6 to 0.9 g/L, 2×10 −6 to 0.09 g/L, 10 −3 to 10 −2 g/L, 10 −3 to 0.1 g/L, 10 −3 to 0.5 g/L, 10 −3 to 0.9 g/L, 10 −3 to 0.09 g/L, 2×10 −3 to 10 −2 g/L, 2×10 3 to 0.1 g/L, 2×10 −3 to 0.5 g/L, 2×10 3 to 0.9 g/L, 2×10 −3 to 0.09 g/L, 0.01 to 0.99 g/L, 0.01 to 0.9 g/L, 0.01 to 05. g/L, 0.01 to 0.2 g/L, 0.01 to 0.1 g/L, 0.1 to 0.99 g/L, 0.1 to 0.9 g/L, 0.1 to 0.5 g/L, 0.1 to 0.2 g/L, 0.5 to 0.99 g/L, 0.5 to 0.9 g/L, or 0.5 to 0.7 g/L.